Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813202 | 0.95 | SLC6A9 (0.54) | SLC6A9KCNH2BRD4LMNAS1PR3 | |
| SCHEMBL5045383 | 0.86 | BRD4 (0.48) | SLC6A9KCNH2BRD4LMNAS1PR3 | |
| SCHEMBL5043956 | 0.85 | SLC6A9 (0.45) | SLC6A9KCNH2BRD4S1PR3 | |
| SCHEMBL5043148 | 0.84 | MAPK1 (0.49) | SLC6A9LMNAS1PR3 | |
| SCHEMBL27990708 | 0.82 | BRD4 (0.54) | SLC6A9BRD4 | |
| SCHEMBL2828648 | 0.82 | SLC6A9 (0.53) | SLC6A9KCNH2BRD4 | |
| SCHEMBL16650725 | 0.82 | BRD4 (0.55) | SLC6A9BRD4 | |
| SCHEMBL2574654 | 0.81 | S1PR3 (0.57) | SLC6A9KCNH2LMNAS1PR3 | |
| SCHEMBL5041677 | 0.81 | FABP4 (0.45) | SLC6A9BRD4LMNAS1PR3 | |
| SCHEMBL20155682 | 0.80 | BRD4 (0.59) | SLC6A9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1828154-B1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-1836168-B1 | BENZOYL-TETRAHYDROPYRIDINE AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | EP | disclosed |
| US-7485637-B2 | Benzoyl-tetrahydropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | US | disclosed |
| WO-2006061135-A1 | PHENYL-PIPERAZIN METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | SLC6A9 1024/4885KCNH2 1197/4885BRD4 2648/4885 |
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | SLC6A9 12/4885KCNH2 977/4885BRD4 2950/4885 |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | SLC6A9 1024/4885KCNH2 1197/4885BRD4 2648/4885 |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | GRIN2A, HTR5A, BACE1 | SLC6A9 844/4885KCNH2 1047/4885BRD4 160/4885 |
| US-20060128712-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HTR5A, NPY5R, GRM5 | SLC6A9 4053/4885KCNH2 228/4885BRD4 453/4885 |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | SLC6A9 23/4885KCNH2 1808/4885BRD4 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.